SILO PHARMA, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
SILO PHARMA, INC. (SILO) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$1.11 million for the 12-month period ending 2025-12-31, per its POS AM filed 2026-04-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-04-14
- SILO PHARMA, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$777.14K.
- SILO PHARMA, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$820.80K, a 200.12% decline from fiscal 2021.
- SILO PHARMA, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2021 was $819.79K.
- SILO PHARMA, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2020 was -$637.88K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$1.11M POS AM · filed 2026-04-14 |
| 2024-12-31 | -$488.23K POS AM · filed 2026-04-14 |
| 2023-12-31 | -$777.14K 10-K · filed 2025-03-28 |
| 2022-12-31 | -$820.80K 10-K · filed 2024-03-25 |
| 2021-12-31 | $819.79K 10-K · filed 2023-03-24 |
| 2020-12-31 | -$637.88K 10-K · filed 2022-03-28 |
| 2019-12-31 | -$212.79K 10-K/A · filed 2021-05-17 |
| 2018-12-31 | -$203.59K 10-K · filed 2020-03-20 |
| 2017-12-31 | -$159.93K 10-K · filed 2019-04-04 |
| 2012-12-31 | -$12.00K 10-K · filed 2013-03-05 |
| 2011-12-31 | -$16.00K 10-K · filed 2013-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |